In pooled results from two 3-month registration studies

BYSTOLIC monotherapy achieved significant BP reductions^2,3

Study Design: Pooled results from two U.S. phase III, 3-month, multicenter, randomized, double-blind, parallel-group, placebo-controlled studies of BYSTOLIC monotherapy for the treatment of mild to moderate hypertension. Primary endpoint was sitting DBP at trough. Mean values at baseline: sitting DBP at trough, 99.3 mm Hg; sitting SBP at trough, 152.3 mm Hg (N=1716; n=1385). One of the two studies included 1.25 mg (n=83), 2.5 mg (n=82), and 30/40 mg (n=166) treatment arms.

BYSTOLIC achieved a reduction in mean BP at 12 weeks across all doses²

• Mean BP at Week 12 for other doses was 141.3/89.5 mm Hg for 5 mg and 142.0/88.7 mm Hg for 10 mg²

BYSTOLIC achieved significant heart rate reductions when used as monotherapy³

• In pooled results from two 3-month registration studies, heart rate reductions of -6.1 BPM to -8.3 BPM demonstrated across the recommended BYSTOLIC dosing range for most patients vs +0.2 BPM for placebo (P<0.001)³

In a 3-month study of patients with mean daytime ambulatory DBP ≥90 mm Hg at baseline by Lacourcière et al

BYSTOLIC monotherapy achieved significant BP reductions⁴

Study Design: Adapted from a 3-month, multicenter, randomized, double-blind, parallel-group, placebo-controlled, multifactorial-design study of BYSTOLIC and hydrochlorothiazide, alone or in combination, for the treatment of mild to moderate hypertension. Mean baseline daytime (from dose time to 8 pm) ambulatory DBP ≥90 mm Hg was required for inclusion. Primary endpoint was clinic sitting DBP at trough. Mean values at baseline: sitting DBP at trough, 100.5 mm Hg; sitting SBP at trough, 158.1 mm Hg (N=240; n=59). This study also included a 1 mg dose arm (n=20).

• Only patients with mean baseline daytime ambulatory DBP ≥90 mm Hg were included in this study⁴

Next: BYSTOLIC—Efficacy in Stage II Hypertension

Next: BYSTOLIC—Efficacy in Stage II Hypertension